Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.

Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.

Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.

PMID:
28646080
2.

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.

Dong JQ, Gosset JR, Fahmi OA, Lin Z, Chabot JR, Terra SG, Le V, Chidsey K, Nouri P, Kim A, Buckbinder L, Kalgutkar AS.

Drug Metab Dispos. 2017 May;45(5):501-511. doi: 10.1124/dmd.116.074476. Epub 2017 Mar 2.

PMID:
28254951
3.

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation.

Chang C, Yang X, Fahmi OA, Riccardi KA, Di L, Obach RS.

Xenobiotica. 2017 Aug;47(8):673-681. doi: 10.1080/00498254.2016.1222640. Epub 2016 Sep 5.

PMID:
27595796
4.

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective.

Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H.

Drug Metab Dispos. 2016 Oct;44(10):1720-30. doi: 10.1124/dmd.116.071076. Epub 2016 Jul 15.

PMID:
27422672
5.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
6.

Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.

Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, Zhang L, Zhao P.

Clin Pharmacol Ther. 2014 Feb;95(2):179-88. doi: 10.1038/clpt.2013.170. Epub 2013 Aug 29.

PMID:
23995268
7.

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L.

Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Review.

PMID:
23792813
8.

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, Lai Y.

Drug Metab Dispos. 2013 May;41(5):966-74. doi: 10.1124/dmd.112.050583. Epub 2013 Feb 7.

PMID:
23393219
9.

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships.

Fahmi OA, Raucy JL, Ponce E, Hassanali S, Lasker JM.

Drug Metab Dispos. 2012 Nov;40(11):2204-11. doi: 10.1124/dmd.112.047456. Epub 2012 Aug 21.

PMID:
22912432
10.

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

Gupta P, Alvey C, Wang R, Dowty ME, Fahmi OA, Walsky RL, Riese RJ, Krishnaswami S.

Br J Clin Pharmacol. 2012 Jul;74(1):109-15. doi: 10.1111/j.1365-2125.2012.04168.x.

11.

How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential.

Kraynov E, Martin SW, Hurst S, Fahmi OA, Dowty M, Cronenberger C, Loi CM, Kuang B, Fields O, Fountain S, Awwad M, Wang D.

Drug Metab Dispos. 2011 Oct;39(10):1779-83. doi: 10.1124/dmd.111.040808. Epub 2011 Jul 18. Review.

PMID:
21768274
12.

A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.

Wakuda H, Nejime N, Tada Y, Kagota S, Fahmi OA, Umegaki K, Yamada S, Shinozuka K.

J Pharm Pharmacol. 2011 Aug;63(8):1015-21. doi: 10.1111/j.2042-7158.2011.01294.x. Epub 2011 Jun 15.

PMID:
21718284
13.

Evaluation of models for predicting drug-drug interactions due to induction.

Fahmi OA, Ripp SL.

Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1399-416. doi: 10.1517/17425255.2010.516251. Review.

PMID:
20955108
14.

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes.

Fahmi OA, Kish M, Boldt S, Obach RS.

Drug Metab Dispos. 2010 Sep;38(9):1605-11. doi: 10.1124/dmd.110.033126. Epub 2010 Jun 21.

PMID:
20566695
15.

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.

Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, Damle B.

J Clin Pharmacol. 2011 Feb;51(2):229-36. doi: 10.1177/0091270010366445. Epub 2010 Apr 6.

PMID:
20371736
16.

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS.

Drug Metab Dispos. 2009 Aug;37(8):1658-66. doi: 10.1124/dmd.108.026252. Epub 2009 Apr 30.

PMID:
19406954
17.

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes.

Fahmi OA, Boldt S, Kish M, Obach RS, Tremaine LM.

Drug Metab Dispos. 2008 Sep;36(9):1971-4. doi: 10.1124/dmd.108.021907. Epub 2008 Jun 2.

PMID:
18519654
18.

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro.

Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D.

Drug Metab Dispos. 2008 Aug;36(8):1698-708. doi: 10.1124/dmd.107.018663. Epub 2008 May 19. Erratum in: Drug Metab Dispos. 2008 Sep;36(9):1975.

PMID:
18490437
19.

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue.

Smith DA, Dickins M, Fahmi OA, Iwasaki K, Lee C, Obach RS, Padbury G, De Morais SM, Ripp SL, Stevens J, Voorman R, Youdim K.

Drug Metab Dispos. 2007 Apr;35(4):697-8. No abstract available.

PMID:
17384203
20.

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM.

Drug Metab Dispos. 2006 Oct;34(10):1742-8. Epub 2006 Jul 12.

PMID:
16837568

Supplemental Content

Loading ...
Support Center